Alendronate-Modified Polymeric Micelles for the Treatment of Breast Cancer Bone Metastasis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Although the prognosis of patients with breast cancer continues to improve, breast cancer metastasis to bones remains high in incidence and challenging to manage. Here, we report the development of bone-homing alendronate (ALN)-anchored biodegradable polymeric micelles for the targeted treatment of metastatic cancer to bone. These micelles exhibited bone protective capacity including the recruitment, differentiation, and resorption activity of the osteoclasts. Encapsulation of docetaxel (DTX), the first-line chemotherapeutic for treatment of metastatic breast cancer, in ALN-modified micelles results in a sustained release, enhanced cytotoxicity, and improved pharmacokinetics. In the syngeneic animal model of late-stage disseminated breast cancer bone metastasis, the treatment with targeted DTX-loaded micelles attenuated the tumorigenesis and significantly improved animal lifespan compared to the conventional surfactant-based formulation (free DTX). These findings indicate potential applications of the osteotropic nanomedicines for bone metastasis treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Successful targeted delivery of these drug-loaded micelles to the tumors using tumor-specific ligands attached to the micelle outer PEG chains were also described [179–181].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [181]
Citations
Cites
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Russell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases
Hartsell, W. F., Scott, C. B., Bruner, D. W., Scarantino, C. W., Ivker, R. A., Roach, M., Suh, J. H., Demas, W. F., Movsas, B., Petersen, I. A., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji139 · Cited by 823
Steenland, E., Leer, J., van Houwelingen, H., Post, W. J., van den Hout, W. B., Kievit, J., de Haes, H., Martijn, H., Oei, B., Vonk, E., et al. (1999) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(99)00110-3 · Cited by 677
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
Ferrari, M., Fornasiero, M. C., & Isetta, A. M. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90187-z · Cited by 565
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Fluorescence probes for critical micelle concentration determination
Goddard, E. D., Turro, N. J., Kuo, P. L., & Ananthapadmanabhan, K. P. (1985) · Langmuir · doi:10.1021/la00063a015 · Cited by 456
Molecular Biology of Bone Metastasis
Kingsley, L. A., Fournier, P. G. J., Chirgwin, J. M., & Guise, T. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0234 · Cited by 435
A novel orthotopic model of breast cancer metastasis to bone
Lelekakis, M., Moseley, J. M., Martin, T. J., Hards, D., Williams, E., Ho, P., Lowen, D., Javni, J., Miller, F. R., Slavin, J., et al. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006689719505 · Cited by 427
Radionuclide Bone Imaging: An Illustrative Review
Love, C., Din, A. S., Tomas, M. B., Kalapparambath, T. P., & Palestro, C. J. (2003) · RadioGraphics · doi:10.1148/rg.232025103 · Cited by 422
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Ashrafizadeh, M., Zarrabi, A., Bigham, A., Taheriazam, A., Saghari, Y., Mirzaei, S., Hashemi, M., Hushmandi, K., Karimi‐Maleh, H., Nazarzadeh Zare, E., et al. (2023) · Medicinal Research Reviews · doi:10.1002/med.21971 · Cited by 207
“Polymeric micelles are of particular interest because of their easy‐to‐tailor structure.(179,180) Paclitaxel drug molecules were entrapped in an acid‐labile, bone‐modified, PEGylated micellar system.”
BackgroundThe past, present, and future of breast cancer models for nanomedicine development
Boix-Montesinos, P., Soriano‐Teruel, P. M., Armiñán, A., Orzáez, M., & Vicent, M. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.018 · Cited by 159
The advances in nanomedicine for bone and cartilage repair
Qiao, K., Xu, L., Tang, J., Wang, Q., Lim, K. S., Hooper, G. J., Woodfield, T. B. F., Liu, G., Tian, K., Zhang, W., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01342-8 · Cited by 138
“Therefore, this system had the potential to treat metastatic bone tumours [80].”
BackgroundJunnuthula, V., Kolimi, P., Nyavanandi, D., Sampathi, S., Vora, L. K., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091860 · Cited by 126
“5 PEG-PGlu-PPhA DOX, ALN Late-stage breast cancer bone metastasis [71]”
BackgroundQin, Y., Tong, F., Zhang, W., Zhou, Y., He, S., Xie, R., Lei, T., Wang, Y., Peng, S., Li, Z., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104645 · Cited by 101
Bone-targeted biomaterials: Strategies and applications
Ren, X., Chen, X., Geng, Z., & Su, J. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137133 · Cited by 98
Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems
Shao, H., & Varamini, P. (2022) · Cells · doi:10.3390/cells11030388 · Cited by 77
“In addition, the development of bone metastasis was delayed, and the weight loss was significantly controlled after the administration of ALN-m/DTX in a mouse BC bone metastasis model induced by injecting 4T1 cells into the left cardiac ventricle of female BALC/c mice [58].”
BackgroundThe optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials
Cheng, X., Wei, J., Ge, Q., Xing, D., Zhou, X., Qian, Y., & Jiang, G. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1856225 · Cited by 43
Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
Dissanayake, R. K., Towner, R. A., & Ahmed, M. (2023) · Cancers · doi:10.3390/cancers15112906 · Cited by 45
“Therefore, treatment with targeted DTX-loaded micelles resulted in the attenuation of tumorigenesis and significantly enhanced animal lifespan, as opposed to the conventional surfactant-based formulation (free DTX) [64].”
BackgroundInfluentialLipid Nanoparticles and Liposomes for Bone Diseases Treatment
Burdușel, A.-C., & Andronescu, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123158 · Cited by 38
“Liposomes [11], lipid nanoparticles [4], micelles [12], and exosomes [13] are examples of nanoscale lipid formulations.”
BackgroundNanomaterial-assisted theranosis of bone diseases
Zheng, K., Bai, J., Yang, H., Xu, Y., Pan, G., Wang, H., & Geng, D. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.014 · Cited by 41
“• attenuate the tumorigenesis and improve animal lifespan [240]”
BackgroundMicelles in Cancer Therapy: An Update on Preclinical and Clinical Status
Kushwaha, P., Aqeel, R., & Srivastava, N. (2021) · Recent Patents on Nanotechnology · doi:10.2174/1872210515666210720125717 · Cited by 30
Advanced nanoparticles, the hallmark of targeted drug delivery for osteosarcoma-an updated review
Ashique, S., Faiyazuddin, M., Afzal, O., Gowri, S., Hussain, A., Mishra, N., Garg, A., Maqsood, S., Akhtar, M. S., & Altamimi, A. S. A. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104753 · Cited by 31
Nano-Drug Delivery Systems for Bone Metastases: Targeting the Tumor–Bone Microenvironment
Bakir, M. A., Dawalibi, A., Mufti, M. A., Behiery, A., & Mohammad, K. S. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050603 · Cited by 26
“In a syngeneic animal model of advanced disseminated breast cancer bone metastasis, treatment with these targeted DTX-loaded micelles reduced tumorigenesis and markedly enhanced animal lifespan relative to the conventional formulation [95].”
Baddam, S. R., Ganta, S., Nalla, S., Banoth, C., Vudari, B., Akkiraju, P. C., Srinivas, E., & Tade, R. S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124346 · Cited by 23
Chen, Z.-H., Du, D., Fu, Y.-F., Wu, J., Guo, D., Li, Y., Chen, M.-N., Yuan, Z., Zhang, K., Zhang, Z., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100747 · Cited by 25
“To increase the polymeric micelle’s affinity for bone tissue, their surfaces are introduced with various bone-targeting moieties, including bisphosphonates (BPs) [12], tetracyclines (TCs) [13], and peptides [14, 15].”
BackgroundDrug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma
Samal, S., Dash, P., & Dash, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s307843 · Cited by 22
“Alendronate (ALN), as a bone homing agent decorated with polymeric micelles encapsulated with docetaxel, has been developed for treating breast cancer bone metastases with better pharmacokinetics and sustained release.(144) However, the major setbacks that micelles possess are the high cost for the preparation of mice…”
BackgroundNew Progress in Improving the Delivery Methods of Bisphosphonates in the Treatment of Bone Tumors
Zhong, Y. M., & Su, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s337925 · Cited by 21
Xia, Q., Zhou, S., Zhou, J., Zhao, X., Saif, M. S., Wang, J. P., Hasan, M., Zhao, M., & Liu, Q. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c02118 · Cited by 19
Breusa, S., Zilio, S., Catania, G., Bakrin, N., Kryza, D., & Lollo, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1125868 · Cited by 18
Current views on in vivo models for breast cancer research and related drug development
Ferreira, T., Azevedo, T., Silva, J., Faustino‐Rocha, A. I., & Oliveira, P. A. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2293152 · Cited by 14
Lim, C. W., & Kim, D. (2021) · Biomaterials Science · doi:10.1039/d0bm01473g · Cited by 12
Lin, M., Zhu, Y., Chang, H., & Zhang, X. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121491 · Cited by 12
Research progress of nanomaterial drug delivery in tumor targeted therapy
Zhang, P., Ye, G., Xie, G., Lv, J., Zeng, X., & Jiang, W. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1240529 · Cited by 13
“DTX micelles can inhibit tumor growth and significantly prolong animal survival in a model of advanced disseminated breast cancer with bone metastases (Liu, 2019).”
BackgroundZhou, L., Lu, R., Liu, Q., Xiao, B., Hai, L., Guo, L., Wu, Y., & Zheng, Y. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102312 · Cited by 10
Huang, H., Asghar, S., Lin, L., Su, C., Yuan, C., Sang, M., & Xiao, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125191 · Cited by 8
Advanced drug delivery systems in breast cancer
Singh, S., Singh, P., Mishra, N., Maurya, P., Singh, N., Nisha, R., & Saraf, S. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85503-7.00028-6 · Cited by 5
Kim, C., Han, S., Joo, Y., Kim, H., Youn, Y. S., Kim, J., Choi, H.-G., Shin, Y., Lim, C., & Oh, K. T. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107320 · Cited by 4
Hanif, S., Shahid, N., Iqbal, J., Yasir, S., Idrees, H. A., Farooq, M. I., Rai, N., Syed, M. A., & Noreen, S. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2681556 · Cited by 3
Ray, S., & Singh, D. (2024) · Current Drug Therapy · doi:10.2174/0115748855302263240910060240 · Cited by 3
Liu, H., Sun, W., Wang, J., Xiang, L., Lin, X., Wang, R., Liu, Q., & Zhang, X. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156138 · Cited by 1
Engineered nanomaterials and microstructures for tissue engineering and regenerative medicine
Martinelli, C., Conci, C., & Raimondi, M. T. (2026) · Nano Futures · doi:10.1088/2399-1984/ae895e · Cited by 1
Management of Peritoneal Surface Malignancies. (Cytoreductive Surgery, HIPEC, PIPAC, and Beyond)
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4670-3
Metadata
- Authors
- Liu, T., Romanova, S., Wang, S., Hyun, M. A., Zhang, C., Cohen, S. M., Singh, R. K., & Bronich, T. K.
- Affiliations
- Nebraska Medical Center (US)
- Corresponding author
- Bronich, Tatiana K.
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-05-31
- Volume
- 16
- Issue
- 7
- Pages
- 2872-2883
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- PMC
- PMC6632075
- OpenAlex
- W2947085578
- Cited by
- 34
- References
- 48
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 7 · 2022: 6 · 2021: 7 · 2020: 3
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U01 CA198910)
- China Scholarship Council ([2003]3009)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- breast cancer bone metastasis, alendronate, polymeric micelles, docetaxel, osteoclastogenesis, osteoclast resorption, biodegradable micelles, targeted drug delivery, sustained drug release, pharmacokinetics
- MeSH terms
- RAW 264.7 Cells, Docetaxel, Animals, Antineoplastic Agents, Bone Neoplasms, Breast Neoplasms, Female, Mice, Inbred BALB C, Micelles, Polymers, Transplantation, Homologous, Treatment Outcome, Alendronate, Cell Line, Tumor, Bone Density Conservation Agents, Mice, Drug Liberation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.